PRTA Live signals | Maximize Profits with Getagraph.com

BUY 98786 min ago

@ $27.01

Issued: 14 Feb 2024 @ 15:42

Return: -21.18%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -1.57 %

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States...

Stats
Today's Volume	331 377
Average Volume	667 727
Market Cap	1.14B
EPS	$0 ( 2024-02-15 )
Next earnings date	( $-1.210 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.71
ATR14	$0.0300 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Ford David A	Buy	85 000	Stock Option (Right to Buy)
2024-03-01	Ford David A	Buy	0
2024-02-27	Zago Wagner M.	Buy	85 000	Stock Option (Right to Buy)
2024-02-27	Walker Karin L	Buy	54 000	Stock Option (Right to Buy)
2024-02-27	Smith Brandon S.	Buy	85 000	Stock Option (Right to Buy)

INSIDER POWER
77.66
Last 98 transactions
Buy: 1 184 000 \| Sell: 192 000

Volume Correlation

Long: -0.39 (neutral)

Short: -0.30 (neutral)

Signal:(32.623) Neutral

Prothena Corporation PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prothena Corporation PLC Correlation - Currency/Commodity

-0.67
( moderate negative )

-0.27
( neutral )

0.00
( neutral )

-0.58
( weak negative )

0.25
( neutral )

0.72
( moderate )

Prothena Corporation PLC Financials

Annual	2023
Revenue:	$91.37M
Gross Profit:	$82.96M (90.79 %)
EPS:	$-2.76

Q4	2023
Revenue:	$316 000
Gross Profit:	$-13.97M (-4 420.57 %)
EPS:	$-1.260

Q3	2023
Revenue:	$84.87M
Gross Profit:	$82.55M (97.27 %)
EPS:	$0.410

Q2	2023
Revenue:	$4.02M
Gross Profit:	$2.22M (55.19 %)
EPS:	$-1.030

Financial Reports:

No articles found.

Prothena Corporation PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.